Compare TOVX & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOVX | BFRI |
|---|---|---|
| Founded | 2001 | 1997 |
| Country | United States | United States |
| Employees | N/A | 94 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 13.2M |
| IPO Year | 2012 | N/A |
| Metric | TOVX | BFRI |
|---|---|---|
| Price | $0.23 | $1.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $2.75 |
| AVG Volume (30 Days) | ★ 1.6M | 399.4K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.57 |
| 52 Week High | $0.86 | $1.21 |
| Indicator | TOVX | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 39.75 | 57.69 |
| Support Level | $0.23 | $0.77 |
| Resistance Level | $0.27 | $1.13 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.32 | 62.87 |
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.